Boston Therapeutics completes Sugardown trial

Sugardown is intended to help in the reduction of post-meal elevation of blood glucose.

In the trial, Sugardown was evaluated in overweight healthy adults with a mean body mass index (BMI) value of 27.3kg/m2.

Boston president Ken Tassey said the study has important endpoints that support their expectation that Sugardown can be a powerful tool for many people who struggle with blood sugar management.

Boston chief technology officer Joan Sellers said they are in the process of summarizing the data to demonstrate the significant reduction in postprandial blood glucose after consumption of Sugardown chewable tablets.